Woman with home décor behind her.
Woman with home décor behind her.

Below is information about patient assistance options that may be available to help you.

XOSPATA® (gilteritinib) Copay Card.
XOSPATA® (gilteritinib) Copay Card.

The XOSPATA Patient Savings Program

The XOSPATA Patient Savings Program* is for eligible patients with commercial prescription insurance. Patients pay as little as

$0 per prescription

You will be enrolled in the program for a 12-month period. You have a maximum copay assistance limit of $7000 per calendar year. There are no income requirements.

If You Have Medicare Part D

XOSPATA Support SolutionsSM can provide information about other resources that may be able to help.

If You Are Uninsured

The Astellas Patient Assistance Program (PAP) provides XOSPATA at no cost to patients who meet the program eligibility requirements. XOSPATA Support SolutionsSM can evaluate whether you are eligible for the PAP.


Call XOSPATA Support SolutionsSM to learn more, Monday through Friday, 8:30 am to 8:00 pm ET.

*By enrolling in the XOSPATA Patient Savings Program ("Program"), the patient acknowledges that they currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance coverage for XOSPATA® (gilteritinib) and is good for use only with a valid prescription for XOSPATA. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who move from commercial insurance to federal or state health insurance will no longer be eligible, and agree to notify the Program of any such change. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of XOSPATA. This offer is not transferrable and cannot be combined with any other offer, free trial, prescription savings card, or discount. The full value of the Program benefits is intended to pass entirely to the eligible patient. This offer is not health insurance and is only valid for patients in the 50 United States, Washington DC, Puerto Rico, Guam and Virgin Islands. This offer is not valid for cash paying patients. This Program is void where prohibited by law. No membership fees. It is illegal to sell, purchase, trade, counterfeit, duplicate, or reproduce, or offer to sell, purchase, trade, counterfeit, duplicate or reproduce the card. This offer will be accepted only at participating pharmacies. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice. The Program has a maximum copay assistance limit of $7,000 per calendar year. After the annual maximum on copay assistance is reached, patient will be responsible for the remaining out-of-pocket costs for XOSPATA. Astellas may reduce or discontinue the copay assistance available under the Program if it determines an enrolled patient is subject to a program offered by a third-party payer or pharmacy benefit manager, or an agent of either, that adjusts patients’ out-of-pocket cost-sharing obligations based on the copay assistance provided by this Program, or excludes the copay assistance provided under this Program from counting towards an enrolled patient’s out-of-pocket cost-sharing obligations (“maximizer” or “accumulator” program). The Program uses advanced logic to identify whether a claim for an enrolled patient is subject to a “maximizer” or “accumulator” program. Unless prohibited by law, Astellas may reduce the cost-sharing assistance available under the Program to a per claim maximum of $25 if it determines a claim for an enrolled patient is subject to a “maximizer” or “accumulator” program.

 

Program is subject to eligibility restrictions and Program terms and conditions.

How XOSPATA Support SolutionsSM Can Help

Case manager helping patients icon.

After you are prescribed XOSPATA, a XOSPATA Support SolutionsSM Case Manager can assist you by:

  • Looking up your insurance coverage for XOSPATA

  • Seeing if your insurance has any coverage requirements or restrictions

  • Identifying any cost-sharing responsibilities you may have through your insurance plan

WHAT IS XOSPATA


XOSPATA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment(s). Your healthcare provider will perform a test to make sure XOSPATA is right for you. It is not known if XOSPATA is safe and effective in children.

What is the most important information I should know about XOSPATA?

XOSPATA may cause serious side effects including Differentiation Syndrome. Differentiation Syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated. Differentiation Syndrome can happen as early as 1 day after starting XOSPATA and during the first 3 months of treatment. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome while taking XOSPATA: fever, cough, dizziness or lightheadedness, rapid weight gain, trouble breathing, swelling of your arms or legs, rash, decreased urination. If you develop any of these symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine and may monitor you in the hospital.

Who should not take XOSPATA?

Do not take XOSPATA if you are allergic to gilteritinib or any of the ingredients in XOSPATA.

What are the possible side effects of XOSPATA?

XOSPATA may cause serious side effects including:

  • See "What is the most important information I should know about XOSPATA?" above.

  • Posterior Reversible Encephalopathy Syndrome (PRES). If you take XOSPATA, you may be at risk of developing a condition involving the brain called PRES. Tell your healthcare provider right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision, or other visual problems. Your healthcare provider will do a test to check for PRES. Your healthcare provider will stop XOSPATA if you develop PRES.

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before you start taking XOSPATA and during your treatment with XOSPATA. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint. The risk of QT prolongation is higher in people with low blood magnesium or low blood potassium levels. Your healthcare provider will do blood tests to check your potassium and magnesium levels before and during your treatment with XOSPATA.

  • Inflammation of the pancreas (pancreatitis). Tell your healthcare provider right away if you have severe stomach (abdomen) pain that does not go away. This pain may happen with or without nausea and vomiting.

The most common side effects of XOSPATA include:

  • Changes in liver function tests

  • Joint or muscle pain

  • Tiredness

  • Fever

  • Pain or sores in mouth or throat

  • Swelling of arms or legs

  • Rash

  • Diarrhea

  • Shortness of breath

  • Nausea

  • Cough

  • Constipation

  • Eye problems

  • Headache

  • Dizziness

  • Low blood pressure

  • Vomiting

  • Decreased urination

Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking XOSPATA if you develop certain side effects during treatment with XOSPATA.

These are not all of the possible side effects of XOSPATA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What should I tell my doctor before taking XOSPATA?

Tell your doctor:

  • About all of your medical conditions.

  • If you have heart problems, including a condition called long QT syndrome.

  • If you have problems with abnormal electrolytes such as sodium, potassium, or magnesium levels.

  • If you are pregnant or plan to become pregnant. XOSPATA can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with XOSPATA or think you may be pregnant.

    • If you are able to become pregnant, your healthcare provider may perform a pregnancy test 7 days before you start treatment with XOSPATA.

    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with XOSPATA and for 6 months after the last dose of XOSPATA.

    • Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with XOSPATA and for 4 months after the last dose of XOSPATA.

     

  • If you are breastfeeding or plan to breastfeed. It is not known if XOSPATA passes into your breast milk. Do not breastfeed during treatment with XOSPATA and for 2 months after the last dose of XOSPATA.

  • About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. XOSPATA may affect the way other medicines work and other medicines may affect how XOSPATA works.

How should I take XOSPATA?

  • Take XOSPATA exactly as your healthcare provider tells you.

  • Do not change your dose or stop taking XOSPATA unless your healthcare provider tells you to.

  • Take XOSPATA 1 time a day at about the same time each day.

  • Swallow XOSPATA tablets whole.

  • XOSPATA can be taken with or without food.

  • Do not break, crush or chew XOSPATA tablets.

  • If you miss a dose of XOSPATA, take your dose as soon as possible on the same day at least 12 hours before your next scheduled dose. Return to your normal schedule the following day. Do not take 2 doses within 12 hours.

Please see Full Prescribing Information, including BOXED WARNING, and Medication Guide.

WHAT IS XOSPATA


XOSPATA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment(s). Your healthcare provider will perform a test to make sure XOSPATA is right for you. It is not known if XOSPATA is safe and effective in children.

What is the most important information I should know about XOSPATA?

XOSPATA may cause serious side effects including Differentiation Syndrome. Differentiation Syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated. Differentiation Syndrome can happen as early as 1 day after starting XOSPATA and during the first 3 months of treatment. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome while taking XOSPATA: fever, cough, dizziness or lightheadedness, rapid weight gain, trouble breathing, swelling of your arms or legs, rash, decreased urination. If you develop any of these symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine and may monitor you in the hospital.

Who should not take XOSPATA?

Do not take XOSPATA if you are allergic to gilteritinib or any of the ingredients in XOSPATA.

What are the possible side effects of XOSPATA?

XOSPATA may cause serious side effects including:

  • See "What is the most important information I should know about XOSPATA?" above.

  • Posterior Reversible Encephalopathy Syndrome (PRES). If you take XOSPATA, you may be at risk of developing a condition involving the brain called PRES. Tell your healthcare provider right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision, or other visual problems. Your healthcare provider will do a test to check for PRES. Your healthcare provider will stop XOSPATA if you develop PRES.

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before you start taking XOSPATA and during your treatment with XOSPATA. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint. The risk of QT prolongation is higher in people with low blood magnesium or low blood potassium levels. Your healthcare provider will do blood tests to check your potassium and magnesium levels before and during your treatment with XOSPATA.

  • Inflammation of the pancreas (pancreatitis). Tell your healthcare provider right away if you have severe stomach (abdomen) pain that does not go away. This pain may happen with or without nausea and vomiting.

The most common side effects of XOSPATA include:

  • Changes in liver function tests

  • Joint or muscle pain

  • Tiredness

  • Fever

  • Pain or sores in mouth or throat

  • Swelling of arms or legs

  • Rash

  • Diarrhea

  • Shortness of breath

  • Nausea

  • Cough

  • Constipation

  • Eye problems

  • Headache

  • Dizziness

  • Low blood pressure

  • Vomiting

  • Decreased urination

Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking XOSPATA if you develop certain side effects during treatment with XOSPATA.

These are not all of the possible side effects of XOSPATA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What should I tell my doctor before taking XOSPATA?

Tell your doctor:

  • About all of your medical conditions.

  • If you have heart problems, including a condition called long QT syndrome.

  • If you have problems with abnormal electrolytes such as sodium, potassium, or magnesium levels.

  • If you are pregnant or plan to become pregnant. XOSPATA can cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with XOSPATA or think you may be pregnant.

    • If you are able to become pregnant, your healthcare provider may perform a pregnancy test 7 days before you start treatment with XOSPATA.

    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with XOSPATA and for 6 months after the last dose of XOSPATA.

    • Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with XOSPATA and for 4 months after the last dose of XOSPATA.

     

  • If you are breastfeeding or plan to breastfeed. It is not known if XOSPATA passes into your breast milk. Do not breastfeed during treatment with XOSPATA and for 2 months after the last dose of XOSPATA.

  • About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. XOSPATA may affect the way other medicines work and other medicines may affect how XOSPATA works.

How should I take XOSPATA?

  • Take XOSPATA exactly as your healthcare provider tells you.

  • Do not change your dose or stop taking XOSPATA unless your healthcare provider tells you to.

  • Take XOSPATA 1 time a day at about the same time each day.

  • Swallow XOSPATA tablets whole.

  • XOSPATA can be taken with or without food.

  • Do not break, crush or chew XOSPATA tablets.

  • If you miss a dose of XOSPATA, take your dose as soon as possible on the same day at least 12 hours before your next scheduled dose. Return to your normal schedule the following day. Do not take 2 doses within 12 hours.

Please see Full Prescribing Information, including BOXED WARNING, and Medication Guide.